Diabetes & Wound Care Centers of America Launches New Specialty Health Clinic Chain for 2025
Diabetes & Wound Care Centers of America (DWCC)
DWCC will partner with select hospitals, providing specialized diabetes management and advanced wound care services across the USA
LAS VEGAS - January 28, 2025 - Diabetes & Wound Care Centers of America (DWCC) today announced its plans to launch a chain of its clinics in 2025. DWCC is introducing its clinic model, effectively providing extremely specialized diabetes management and advanced wound care services to communities that previously had no, or few treatment resources.
DWCC treats a significant and common problem facing diabetes patients. The disease can damage a patient's skin and reduce its ability to heal itself. As a result, diabetes patients often develop hard-to-treat wounds that are painful and have the potential to become costly and even life-threatening if not addressed promptly and professionally.
The launch of the chain also offers a solution to a healthcare access problem that affects many Americans. Across the United States, complications from diabetes and treatment of such has imposed a strain on healthcare institutions. The Las Vegas-based company solves this problem through accessible healthcare. Executing this program involves initiating strategic partnerships with selected hospitals.
Diabetes care has previously been folded into existing healthcare systems. DWCC is changing this dynamic through specialized services. It has the ability to provide optimized outcomes and the highest standard of care for patients in need of professional care and measurable results.
'Despite recent healthcare advancements, many patients across the United States still face significant obstacles to accessing comprehensive care,' said Jeff Russell, President, and founder of DWCC, who brings decades of related expertise to his role. 'While hospitals work to meet the growing demand for specialized care, patients experience delayed treatment, worsened health outcomes, and higher costs.'
'We use the latest, state-of-the-art technologies to treat non-healing wounds by integrating skin substitutes, to name one example of our differentiated approach,' said Russell. 'We are incorporating innovative treatment strategies for problematic diabetes patients who are not seeing positive results with their previous or existing treatments.'
Russell added, 'Our focus is on secondary markets and rural markets that heretofore have not had gold standard treatments for critical complications of diabetes and will just not heal. We will address those patients exposed to infections and in some cases, amputations.'
DWCC has designed healing program standards for diabetes management and chronic wound care, offering bespoke patient treatment services for optimized outcomes and an elevated standard of care, with the focus of delivering optimal results.
Country: United States
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Las Vegas to build new recuperative care center facility
LAS VEGAS (KLAS) — In just a few weeks, the Recuperative Care Center will transition to the Health and Wellness Center on Main Street while construction gets underway for their brand new facility. Arcelia Barajas, the Director of Neighborhood Services for the City of Las Vegas, is pleased to see things moving forward. 'There is a significant need for this program and work here. We have a lot of folks who are homeless and who are discharged from the hospital, and they don't have anywhere to recuperate,' Barajas told 8 News Now. While the location will stay the same, located on Main Street downtown, the current building will be completely demolished this year, with a new two-story facility built by 2027. The new building will have nearly 80 beds available for those. Sharie McClellan is one of those people in need. McClellan is dealing with her own health struggles. She's been at the Recuperative Care Center for 5 months after a doctor referred her from the Courtyard Homeless Resource Center. 'Thank god this doctor happened to walk by me. He noticed I was out of breath, and I told him I was just released from the hospital and had a blood clot on my lung. He got me over to the facility within hours. It was a true blessing,' she said. Those at the forefront in helping these individuals with their acute medical needs, like program manager Miguel Urena, have seen it all. 'We have 24-hour nursing care here. We do IV infusions to wound cares. We see a lot of burns during the summer. People are falling down or don't have the appropriate footwear and because of that get severely hurt,' Urena added. Also, he said providing care for hospice patients is a main component in what they do. 'It's better for them to be here with us than for them to pass away in a park or behind a dumpster somewhere,' he added. The renovation process of the new facility will take up to 18 months to complete. Those at the recuperative Care Center must be referred by a doctor to gain access. Initially, the center was created to help homeless individuals suffering from COVID, but due to the dire need for basic healthcare services, it grew to more of a rehab facility for those who were previously admitted to the hospital. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Miami Herald
3 hours ago
- Miami Herald
Lilly's experimental obesity drug shows promise in early study
An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothold in the obesity market. The drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months, according to an abstract posted Friday ahead of the American Diabetes Association conference in Chicago. The drug is moving to the next stage of development and researchers will present details on dosing and safety at the conference next week. "The data look particularly strong, and should push the program back into investor conversations," Cantor Fitzgerald analyst Prakhar Agrawal wrote in a note to investors. Lilly has shared few details about eloralintide before now, as it's still in the early stages of testing. It's part of a class of drugs that mimic the hormone amylin, which slows digestion and makes people feel full longer. They're thought to be a gentler option for losing weight than currently available injections like Zepbound and Wegovy, which often have side effects like nausea and vomiting. The study enrolled 100 patients who were given different doses of the experimental drug or a placebo for 12 weeks. Weight loss ranged from 2.6% to 11.3%, according to the abstract. Gastrointestinal side effects were relatively minimal, with about 10% of patients experiencing diarrhea and 8% vomiting. Few details were provided, however, including information on risks and benefits based on dose. The promise of drugs that are easier to take than blockbusters like Lilly's Zepbound and its rival Wegovy, from Novo Nordisk A/S, has drawn increasing interest from companies hoping for a piece of pharma's hottest market. In March, Roche Holding AG entered into a $5.3 billion deal to co-develop and commercialize Zealand Pharma A/S' amylin drug, called petrelintide. It is seen as the one to beat in the amylin class, with early trials showing patients lost as much as 8.6% of their body weight in four months, with less nausea than Lilly and Novo's current therapies. AbbVie Inc. agreed to pay as much as $2.2 billion in March for an amylin drug from Danish biotech Gubra A/S, marking its first foray into the obesity market. New York-based startup Metsera Inc. is developing a related compound that may be taken less frequently than weekly shots like Zepbound and Wegovy. Lilly is already a leader in the obesity market, where Zepbound is capturing the majority of new prescriptions. The company has several promising next-generation products in the late stages of development, including a pill called orforglipron and an experimental shot that's thought to be even more effective for weight loss. The company is studying eloralintide alone and in combination with Zepbound - similar to the approach Novo is taking with its next-generation drug CagriSema, which combines an amylin component with semaglutide, the backbone of Wegovy and the diabetes drug Ozempic. Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
Associated Press
3 hours ago
- Associated Press
Notification of Data Security Incident
LAS VEGAS, June 13, 2025 /PRNewswire/ -- Effortless Office Enterprises, LLC ('Effortless Office') has learned of a data security incident that may have involved personal and/or protected health information of certain employees and patients of Nevada Heart and Vascular ('NHV'). Notice of this incident has been sent to certain affected current/former employees, patients, and/or associated parties and provided resources to assist them. Upon learning of suspicious activity temporarily within its computer network, Effortless Office promptly took steps to secure the environment and began an investigation to determine the nature and scope of the issue. In addition, they began working to restore impacted systems as quickly as possible and engaged digital forensics specialists to conduct an investigation. The investigation determined that unauthorized access occurred at certain times between May 9, 2024 and July 23, 2024. After determining that personal information may have been impacted, Effortless Office completed a comprehensive programmatic and manual review to identify what personal information was impacted and to whom it belonged. On May 12, 2025, Nevada Heart & Vascular Center, LLP learned that certain personal information was impacted in connection with the incident. The following information may have been affected as a result of the incident: Social Security number, taxpayer identification number, driver's license or state identification, passport number, date of birth, account number, routing number, security code, payment card number, payment card pin, payment card expiration date, health insurance information, medical information, and biometric data. On June 13, 2025, a notification letter was mailed to affected individuals, for whom address information was available. A toll-free call center has been established to answer questions about the incident and address related concerns. Call center representatives are available Monday through Friday from 9:00 am to 9:00 pm Eastern Time and can be reached at 1-855-200-7910. The privacy and protection of personal and protected health information is a top priority for Effortless Office, which deeply regrets any inconvenience or concern this incident may cause. View original content: SOURCE Effortless Office Enterprises, LLC
